When T cells from a bone marrow donor begin to attack the host within 3 months after
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease …

Alpha1-Antitrypsin Deficiency AAT is a protease inhibitor targeting neutrophil elastase. It
prevents the destruction of tissue, particularly in the lung, from elastase activity. AAT …

Abstract Alpha‐1 antitrypsin (AAT) deficiency is an under‐recognized hereditary disorder
associated with the premature onset of chronic obstructive pulmonary disease, liver cirrhosis …

The rationale of α1-antitrypsin (AAT) augmentation therapy to treat progressive emphysema
in AAT-deficient patients is based on inhibition of neutrophil elastase; however, the benefit of …

Graft-vs. host disease (GVHD), both acute and chronic are among the chief non-relapse
complications of allogeneic transplantation which still cause substantial morbidity and …

Graft versus host disease (GVHD) remains a major cause of morbidity and mortality
following allogeneic hematopoietic stem-cell transplantation (HSCT). Despite the use of …

Summary Alpha-1 antitrypsin deficiency (AATD) arises from mutations in the SERPINA1
gene encoding alpha-1 antitrypsin (AAT) that lead to AAT retention in the endoplasmic …

Abstract α 1-Antitrypsin (AAT) is a 52-kDa circulating serine protease inhibitor. Production of
AAT by the liver maintains 0.9-1.75 mg/mL circulating levels. During acute-phase responses …

Corticosteroid resistance after acute graft-versus-host disease (SR-aGVHD) results in high
morbidity and mortality after allogeneic hematopoietic cell transplantation. Current …

Alpha-1 antitrypsin (A1AT) is an acute-phase protein, and is best known as an inhibitor of
the serine proteases, specifically, neutrophil elastase, proteinase 3, and cathepsin G. The …